| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf80785b2dcca083534e19e9f9172751
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_937c0c65e97a4a187f98a0d1b68595d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40d60ca869f09093e64a5b8371bea0fa |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate |
2011-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3eca385da19afe67fbd01095100b4bd3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2408a8921e30f82dbe9df594ecdbebfd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a99a306f41d36021d3e612df6004098 |
| publicationDate |
2015-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8957077-B2 |
| titleOfInvention |
Pyrazolopyrimidine PDE 10 inhibitors |
| abstract |
The present invention is directed to pyrazolopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11155560-B2 |
| priorityDate |
2010-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |